Literature DB >> 15082126

Stimulus-dependent specificity for annexin 1 inhibition of the inflammatory nociceptive response: the involvement of the receptor for formylated peptides.

Stefano Pieretti1, Amalia Di Giannuario, Milena De Felice, Mauro Perretti, Giuseppe Cirino.   

Abstract

In this study we investigated how the peptides derived from the glucocorticoid-inducible protein annexin 1 are able to alter the nociceptive threshold of mice. The effects of the annexin1 fragment 2-26 (Anxa1(2-26)) on nociceptive threshold were studied using both chemical (formalin test) and thermal (hot plate and tail flick test) nociceptive stimuli on mice. Subcutaneous administration of Anxa1(2-26) into the dorsal surface of the mouse's hind paw was able to selectively reduce formalin-induced nociceptive behavior in the last phase of the test. The same effect was observed after intracerebroventricular administration, however, this was not the case when performing the hot plate or tail flick tests. Of the shortest Anxa1(2-26)-derived peptides, Anxa1(2-12) reduced the nociceptive response to formalin, however, the Anxa1(2-6) did not. The possible involvement of the receptors for formylated peptide in the anti-nociceptive action of Anxa1(-26) and Anxa1(2-12) was studied, choosing the formalin test. We found that the formyl peptide receptor agonist formyl-MLF (fMLF) induced anti-nociceptive effects in the formalin test both after the peripheral and central administration. The formyl peptide receptor antagonist N-t-butoxycarbonyl-MLP did not alter the response to formalin, but it was able to block the anti-nociceptive effects of Anxa1(2-26,) Anxa1(2-12) and fMLF after peripheral or central administration. These results indicate that exogenously administered Anxa1 can peripherally and centrally inhibit the nociceptive transmission associated with inflammatory processes through a mechanism that involves formyl peptide receptors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15082126     DOI: 10.1016/j.pain.2004.01.009

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  17 in total

1.  Biological active analogues of the opioid peptide biphalin: mixed α/β(3)-peptides.

Authors:  Adriano Mollica; Francesco Pinnen; Roberto Costante; Marcello Locatelli; Azzurra Stefanucci; Stefano Pieretti; Peg Davis; Josephine Lai; David Rankin; Frank Porreca; Victor J Hruby
Journal:  J Med Chem       Date:  2013-04-12       Impact factor: 7.446

2.  Novel cyclic biphalin analogue with improved antinociceptive properties.

Authors:  Adriano Mollica; Alfonso Carotenuto; Ettore Novellino; Antonio Limatola; Roberto Costante; Francesco Pinnen; Azzurra Stefanucci; Stefano Pieretti; Anna Borsodi; Reza Samavati; Ferenc Zador; Sándor Benyhe; Peg Davis; Frank Porreca; Victor J Hruby
Journal:  ACS Med Chem Lett       Date:  2014-07-14       Impact factor: 4.345

Review 3.  Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.

Authors:  I A Schepetkin; A I Khlebnikov; M P Giovannoni; L N Kirpotina; A Cilibrizzi; M T Quinn
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

4.  Synthesis, enantioresolution, and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonists.

Authors:  Agostino Cilibrizzi; Igor A Schepetkin; Gianluca Bartolucci; Letizia Crocetti; Vittorio Dal Piaz; Maria Paola Giovannoni; Alessia Graziano; Liliya N Kirpotina; Mark T Quinn; Claudia Vergelli
Journal:  Bioorg Med Chem       Date:  2012-04-27       Impact factor: 3.641

5.  2-Arylacetamido-4-phenylamino-5-substituted pyridazinones as formyl peptide receptors agonists.

Authors:  Claudia Vergelli; Igor A Schepetkin; Giovanna Ciciani; Agostino Cilibrizzi; Letizia Crocetti; Maria Paola Giovannoni; Gabriella Guerrini; Antonella Iacovone; Liliya N Kirpotina; Andrei I Khlebnikov; Richard D Ye; Mark T Quinn
Journal:  Bioorg Med Chem       Date:  2016-04-08       Impact factor: 3.641

6.  Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists.

Authors:  Maria Paola Giovannoni; Igor A Schepetkin; Agostino Cilibrizzi; Letizia Crocetti; Andrei I Khlebnikov; Claes Dahlgren; Alessia Graziano; Vittorio Dal Piaz; Liliya N Kirpotina; Serena Zerbinati; Claudia Vergelli; Mark T Quinn
Journal:  Eur J Med Chem       Date:  2013-04-08       Impact factor: 6.514

7.  Increased susceptibility of annexin-A1 null mice to nociceptive pain is indicative of a spinal antinociceptive action of annexin-A1.

Authors:  S S Ayoub; S Yazid; R J Flower
Journal:  Br J Pharmacol       Date:  2008-05-12       Impact factor: 8.739

8.  Mycobacteria attenuate nociceptive responses by formyl peptide receptor triggered opioid peptide release from neutrophils.

Authors:  Heike L Rittner; Dagmar Hackel; Philipp Voigt; Shaaban Mousa; Andrea Stolz; Dominika Labuz; Michael Schäfer; Michael Schaefer; Christoph Stein; Alexander Brack
Journal:  PLoS Pathog       Date:  2009-04-03       Impact factor: 6.823

9.  Electroacupuncture decreases inflammatory pain through a pro-resolving mechanism involving the peripheral annexin A1-formyl peptide receptor 2/ALX-opioid receptor pathway.

Authors:  Cintia Vieira; Daiana C Salm; Verônica V Horewicz; Daniela D Ludtke; Aline A Emer; Júlia F Koerich; Gustavo Mazzardo; Sayron Elias; Ari O O Moré; Leidiane Mazzardo-Martins; Francisco J Cidral-Filho; William R Reed; Anna Paula Piovezan; Daniel F Martins
Journal:  Pflugers Arch       Date:  2021-01-20       Impact factor: 3.657

10.  Anti-allergic cromones inhibit histamine and eicosanoid release from activated human and murine mast cells by releasing Annexin A1.

Authors:  Samia Yazid; Ajantha Sinniah; Egle Solito; Virginia Calder; Rod J Flower
Journal:  PLoS One       Date:  2013-03-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.